Day: December 17, 2025

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026. Presentation DetailsDate: Wednesday, January 14, 2026 Time: 7:30 AM PT Webcast Link: cmpx.info/jpmorgan Virtual/Replay availability: The presentation will be archived on Compass’ Events page. Investors interested in scheduling one-on-one meetings with Compass on January 14, 2026 should contact their J.P. Morgan representative. Compass will also host investor meetings as part of the LifeSci Partners Corporate Access Event, January 12 & 13, 2026 in San Francisco, CA. Interested investors should contact their LifeSci representative...

DALLAS, Dec. 17, 2025 (GLOBE NEWSWIRE) — Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced that its Board of Directors (the “Board”) has appointed Peter T. Cangany Jr. as Chairman of the Board, effective December 15, 2025. Mr. Cangany has served as a director of Beneficient and as Chairman of its independent Audit Committee since 2019. He brings decades of leadership experience in financial reporting, accounting, and corporate governance within the financial services industry. Mr. Cangany retired as a partner of Ernst & Young LLP (“EY”) in 2017 after nearly 40 years with the firm, including more than two decades as a partner. During his tenure at...

Distribution network coverage expanded to a total of 39 countries GARDEN CITY, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the recent signing of several key international distribution agreements for LungFit® PH, expanding its network to include Germany, Brazil, Austria, the Netherlands and Sri Lanka. These agreements bring the total international coverage to 39 countries, representing a combined population of more than three billion people. “We are encouraged by the rapid expansion of LungFit PH’s international footprint over the past nine months. With access to 39 countries outside of the United States,...

Phase III is intended to generate meaningful biological data on potential drug compounds prioritized by YuvaBio’s classifier, which applies proprietary machine-learning methods to identify candidates targeting muscle preservation through improvements in mitochondrial function. Experimental work designed to identify candidates that may upregulate ANT1, a key gene involved in metabolic function and muscle integrity. Phase III is expected to accelerate discovery on small-molecule candidates which may promote mitochondrial health and support muscle preservation: using an exclusive dataset on mitochondrial biogenesis, the AI prioritization focuses experimental testing on the most promising candidates, reducing the number of compounds advanced for subsequent development.NEWPORT BEACH, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) — NorthStrive...

WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced it will be providing ACR-368 and ACR-2316 clinical data and other updates in January 2026. Topics will include:Updated interim ACR-368 clinical data from the ongoing registrational-intent Phase 2b study as well as an update on the additional recently initiated tumor biopsy-independent Phase 2b arm, and the planned...

Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial Flexibility BroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board on Growth and Operating Opportunities HOLLISTON, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today announced it entered into an agreement with BroadOak Capital Partners (collectively, “BroadOak”), a life-sciences-focused investment and advisory firm, to provide a $40 million credit facility comprised of three term loans, all of which will be funded on December 17, 2025. The proceeds of the facility will be used to retire the Company’s existing debt obligations and associated fees, and strengthen its balance sheet and capital structure. Comprehensive Growth...

New leveraged ETPs on Spotlight (SEK): Bull Bitcoin X2 Valour and Bull Ethereum X2 Valour deliver 2x daily exposure to BTC and ETH in a regulated, exchange-traded format (no wallets or margin; 1.9% management fee). Designed for familiar Nordic workflows: Built for investors who want amplified exposure without digital wallets or margin accounts, leveraging the region’s long standing familiarity with Bull and Bear style products. Expanding beyond spot products: Strengthens Valour’s product breadth with structured and enhanced exposure offerings that complement its diversified lineup across next generation crypto themes.TORONTO, Dec. 17, 2025 (GLOBE NEWSWIRE) — DeFi Technologies (the “Company” or “DeFi Technologies”) (Nasdaq: DEFT) (CBOE CA: DEFI) (GR: R9B), a financial technology company bridging the gap between traditional capital...

Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater China SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO® (aficamten) has been approved by the China National Medical Products Administration (NMPA) for the treatment of adults with New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM), to improve exercise capacity and symptoms. Under the terms of its license and collaboration agreement with Cytokinetics, Sanofi has exclusive rights to develop and commercialize MYQORZO for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China. The approval...

WINNIPEG, Manitoba, Dec. 17, 2025 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) announces that it presented new clinical and scientific data at the Innovations in Wound Healing (“IWH”) Annual Meeting, which took place in Key West, Florida December 11-14, 2025.  At this year’s conference, Kane Biotech shared case study data from across its wound care portfolio, underscoring the company’s commitment to addressing complex and high-burden health conditions. The link to the presentations can be found here and include:Clinical outcomes reported from case studies using Kane’s advanced wound gel platform, demonstrating improved healing trajectories in chronic wounds. Versatility over multiple sites and standards of care, featuring efficacy over different application frequencies, dressing and...

Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in September 2025 Combined disease control rate of 90% across both Phase 1a and Phase 1b patients with confirmed partial and minor responses observed LONDON and PHILADELPHIA, Dec. 17, 2025 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced compelling new data in patients with salivary gland cancer (SGC) enrolled in the ongoing Phase 1b trial of faridoxorubicin (AVA6000). The data show confirmed partial and minor responses, consistent with data previously reported from the Phase 1a part of the study. Faridoxorubicin is the first peptide drug conjugate (PDC) in Avacta’s pipeline. It consists of...